For research use only. Not for therapeutic Use.
TNCA(CAT: I009836), also known as Lycoperodine-1, is indeed a high-affinity ligand for the calcium-sensing receptor (CaSR) and exhibits co-agonist activity. The calcium-sensing receptor is a G-protein coupled receptor involved in the regulation of calcium homeostasis. TNCA has been studied for its pharmacological effects on CaSR activation. It acts as a co-agonist along with extracellular calcium, enhancing the receptor’s signaling response. TNCA’s ability to modulate the calcium-sensing receptor has implications for various physiological processes, including calcium metabolism and parathyroid hormone secretion. Its role as a CaSR ligand makes it a valuable tool for research and potentially as a therapeutic agent targeting CaSR-related conditions
| Catalog Number | I009836 |
| CAS Number | 42438-90-4 |
| Synonyms | Lycoperodine-1; TNCA; L-1,2,3,4-Tetrahydronorharman-3-carboxylic acid;(3S)-2,3,4,9-Tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid |
| Molecular Formula | C12H12N2O2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (3S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid |
| InChI | InChI=1S/C12H12N2O2/c15-12(16)10-5-8-7-3-1-2-4-9(7)14-11(8)6-13-10/h1-4,10,13-14H,5-6H2,(H,15,16)/t10-/m0/s1 |
| InChIKey | FSNCEEGOMTYXKY-JTQLQIEISA-N |
| SMILES | C1C(NCC2=C1C3=CC=CC=C3N2)C(=O)O |
| Reference | 1:Int J Exp Pathol. 1992 Dec;73(6):733-40. The effect of thionaphthene-2-carboxylic acid (TNCA) on bone structure in the rat: a histomorphometric study.Nyska M,Nyska A,Waner T,Wolter K, PMID: 1493102 PMCID: PMC2002431 </br><span>Abstract:</span> Thionaphthene-2-carboxylic acid (TNCA) has been shown to decrease osteoclast-mediated bone resorption in vitro and has shown efficacy in animal models of hypercalcaemia of malignancy. In this study, the effects of TNCA on the tibial proximal epiphysis and the sternum have been quantified by image analysis in rats administered the drug orally for 90 days at 75, 125 or 250 mg/kg/day. The amount of bone in the subepiphyseal area and sternum was increased in a dose-related manner. TNCA exerted a biphasic effect on the height of the epiphyseal plate. It was stimulatory at the low dosage and inhibitory at the high dose. This study constitutes the first of its kind to demonstrate the in-vivo effect of TNCA on the bones of rats. |
